0.6854

4.37% -0.0313

Pre-market: .72 0.0346 +5.05%

Atossa Therapeutics Inc (ATOS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Atossa Therapeutics Inc stock is traded at $0.6854, with a volume of 1.05M. It is down -4.37% in the last 24 hours and down -15.90% over the past month. Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Previous Close:

$0.7167

Open:

$0.7027

24h Volume:

1.05M

Relative Volume:

1.40

Market Cap:

$86.22M

Revenue:

Net Income/Loss:

$-26.91M

P/E Ratio:

-3.1155

EPS:

-0.22

Net Cash Flow:

$-19.57M

1W Performance:

-8.67%

1M Performance:

-15.90%

6M Performance:

-54.91%

1Y Performance:

-45.60%

1-Day Range:

$0.66

$0.74

1-Week Range:

$0.66

$0.769

52-Week Range:

$0.66

$2.31

Atossa Therapeutics Inc Stock (ATOS) Company Profile

Name

Atossa Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (679)

Phone

206.588.0256

Address

10202 5TH AVENUE NE, SEATTLE, WA

Employee

Twitter

@atossainc

Next Earnings Date

2024-12-11

Latest SEC Filings

ATOS's Discussions on Twitter

Compare ATOS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATOS Atossa Therapeutics Inc	0.6854	86.22M	0	-26.91M	-19.57M	-0.22
VRTX Vertex Pharmaceuticals Inc	502.92	129.14B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.61	74.41B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	581.21	35.31B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.75	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.57	27.35B	3.32B	-860.46M	-1.04B	-8.32

Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-26-18	Initiated	Maxim Group	Buy

Atossa Therapeutics Inc Stock (ATOS) Latest News

01:43 AM

HC Wainwright Reiterates Buy Rating for Atossa Therapeutics (NASDAQ:ATOS) - Defense World

01:43 AM

Mar 12, 2025

Atossa Genetics stock hits 52-week low at $0.7 amid market challenges - Investing.com Australia

Mar 12, 2025

Atossa Genetics stock hits 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa

Mar 12, 2025

Mar 11, 2025

Nothing is Better Than Atossa Therapeutics Inc (ATOS) stock at the moment - SETE News

Mar 11, 2025

Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses - Marketscreener.com

Mar 11, 2025

Atossa Therapeutics to pursue metastatic breast cancer for (Z)-endoxifen - TipRanks

Mar 11, 2025

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications - The Manila Times

Mar 11, 2025

Breakthrough: New Breast Cancer Drug Shows 3x Better Survival Rate Than Standard Treatment - StockTitan

Mar 11, 2025

Mar 04, 2025

Atossa Genetics stock hits 52-week low at $0.72 - Investing.com

Mar 04, 2025

Feb 24, 2025

Atossa Therapeutics faces Nasdaq delisting over bid price By Investing.com - Investing.com South Africa

Feb 24, 2025

Atossa Therapeutics faces Nasdaq delisting over bid price - Investing.com

Feb 24, 2025

Feb 22, 2025

Atossa Therapeutics reports progress in breast cancer treatments - MSN

Feb 22, 2025

Feb 20, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Up 5.8% in January - MarketBeat

Feb 20, 2025

Feb 19, 2025